Pacira BioSciences (PCRX) investor relations material

Strategic overview and priorities

• Focused on non-opioid pain management with three marketed products and a growing pipeline.

• Implemented a 'five by 30' strategy targeting 3 million patients, double-digit CAGR, and margin expansion by 2030.

• Achieved strong Q1 results: EXPAREL sales up 5%, ZILRETTA up 15%, iovera up 21% year-over-year.

• Restructured sales teams and signed new partnerships to drive growth.

• Emphasizing expansion of covered lives and ex-U.S. agreements for future growth.

Growth drivers and market access

• NOPAIN Act, effective January 2025, is a key catalyst for Medicare outpatient volume growth.

• Volume growth accelerated from 3% to 8% in 2023, continuing into Q1 2024.

• Ex-U.S. expansion through LG Chem in Asia-Pacific and ongoing efforts to increase U.S. covered lives outside bundled payments.

• Additional growth expected from future price increases and broader payer adoption.

Intellectual property and exclusivity

• Strengthened patent portfolio for EXPAREL, now with 21 Orange Book-listed patents.

• Favorable settlement delays generic entry until 2030, with gradual entry until 2039.

• Ongoing legal proceedings expected to last through 2030 for other ANDA filings.

• Continued innovation and new patent filings anticipated in 2024 and 2025.